Tiziana Life Sciences Ltd. Common Shares
TLSATiziana Life Sciences Ltd. is a biotechnology company focused on developing therapies for serious diseases, including cancer, inflammatory, and autoimmune disorders. The company leverages novel monoclonal antibody and small molecule platforms to advance clinical and preclinical candidates through its research and development pipeline. Headquartered in the UK, Tiziana Life Sciences aims to address unmet medical needs with innovative treatments.
Company News
Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a randomized, double-blind, placebo-controlled trial (INFORM-MS) evaluating intranasal foralumab in 48 patients with non-active Secondary Progressive Multiple Sclerosis. Topline data is expected in late Q3 2026 and will be presented at the ACTRIMS/ECTRIMS meeting in Oc...
Tiziana Life Sciences announced positive preclinical data published on bioRxiv showing that intranasal foralumab, an anti-CD3 monoclonal antibody, significantly reduces neuroinflammation and improves cognitive function in a Long COVID mouse model. The study, conducted by researchers from Yale University and Harvard Medical School, demonstrated th...
Tiziana Life Sciences (NASDAQ: TLSA) closed an oversubscribed $8.8 million registered direct offering of 7.04 million ordinary shares at $1.25 per share, with warrants providing up to $10.56 million in additional potential proceeds. The offering was led by CEO Ivor Elrifi and Executive Chairman Gabriele Cerrone. Proceeds will fund Phase 2 clinica...
Tiziana Life Sciences closed an oversubscribed $8.8 million registered direct offering of 7.04 million ordinary shares at $1.25 per share, with warrants providing up to $10.56 million in additional potential proceeds. The funding will support completion of Phase 2 clinical trials for intranasal foralumab in na-SPMS and MSA patients. CEO Ivor Elri...
Tiziana Life Sciences is launching a Phase 2 clinical trial for intranasal foralumab to treat early Alzheimer's disease, targeting neuroinflammation in combination with existing anti-amyloid therapies like Leqembi.
